Limaca Medical
Electro-mechanically Driven Endoscopic Ultrasound-guided Biopsy
Company Overview
Snapshot
Founded in January 2015 by Assaf Klein and Iyad Khamaysi, Limaca Medical operates with 1–10 employees. The company has raised $1.25 million across two funding rounds and received Breakthrough Device designation from the FDA in May 2022 for its Precision-GI product.
Business overview
Limaca Medical is a Health Tech & Life Sciences company focused on developing advanced medical technologies for improved diagnosis of gastrointestinal system tumors. The company's core product, KORA, is an electro-mechanically driven endoscopic ultrasound-guided biopsy device designed to obtain higher-quality core tissue for superior histopathologic analysis. Initially targeting pancreatic tumors, Limaca Medical plans to expand into liver and lung cancer markets, operating within the diagnostics and medical devices sectors.
Strategic signal
In November 2024, Limaca's Precision-GI was granted CMS Transitional Pass-Through (TPT) payment. This development is a significant market validation, indicating that the Centers for Medicare & Medicaid Services recognize the device's innovative nature and potential to improve patient outcomes, thereby facilitating broader adoption and reimbursement in the US healthcare system.
Log in to access full profile ›Company Intelligence Q&A
- What is Limaca Medical's primary product?
- Limaca Medical's primary product is KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy device designed to improve the diagnosis of gastrointestinal system tumors by obtaining higher-quality core tissue.
- When did Limaca Medical receive FDA Breakthrough Device designation?
- Limaca Medical received FDA Breakthrough Device designation for its Precision-GI product in May 2022.
- When did Limaca Medical announce its partnership in Japan?
- Limaca Medical announced a partnership with HekaBio in Japan on May 16, 2022, to distribute its Precision-GI device in the Japanese market.
- What significant payment status did Limaca Medical's Precision-GI receive?
- In November 2024, Limaca's Precision-GI was granted CMS Transitional Pass-Through (TPT) payment, facilitating its reimbursement in the US market.
- When did Limaca Medical launch its Precision-GI device in the US market?
- Limaca Medical launched its Precision-GI endoscopic automated motorized EUS biopsy device in the US market in February 2025.